Globus Medical Inc. Class A Common Stock vs Koninklijke Philips NV — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while Koninklijke Philips NV trades at $25.28 (market cap $24.24B). The key difference: Koninklijke Philips NV is far larger — about 2.4× Globus Medical Inc. Class A Common Stock's market cap, and Koninklijke Philips NV pays a 4.07% dividend while Globus Medical Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and Koninklijke Philips NV for 84 Days on average.
| GMED | PHG | |
|---|---|---|
Market Cap | $10.25B | $24.24B |
Volume | 1,108,124 | 982,766 |
Sector | Health | Health |
52-Week High | $96.82 | $32.91 |
52-Week Low | $58.33 | $23.81 |
Typical Hold Time | 0 Days | 84 Days |
Enterprise Value | $9.76B | $30.57B |
Dividend Yield | — | 4.07% |
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
PHG trades at $25.00, up 1.05% today, with a bullish technical signal despite mixed oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $0.57 exceeding the $0.40 estimate. Revenue for 2025 was $17.83 billion, with a net income margin of 5.01%, showing a recovery from prior losses. Recent news highlights product launches and strategic partnerships in healthcare technology.
The outlook is cautiously optimistic, supported by earnings momentum and innovation, but risks include competitive pressures and debt levels. Analysts are mixed, with a 'Hold' consensus, while institutional buying activity indicates underlying confidence. Valuation metrics like a P/E of 19.49 suggest the stock is fairly priced relative to peers.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. About 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, image-guided therapy solutions and healthcare informatics. The connected care segment (27% of revenue) encompasses monitoring and analytics systems for hospitals and sleep and respiratory care devices, whereas the personal health business (remainder of revenue) includes electric toothbrushes and men's grooming and personal-care products. In 2021, Philips generated EUR 17.2 billion in sales and had 80,000 employees in over 100 countries.
Read more on PHG →